-+ 0.00%
-+ 0.00%
-+ 0.00%

Emergent BioSolutions Awarded $22.3M Contract Modification To Provide BioThrax To U.S. Department Of War

Benzinga·11/04/2026 21:23:39

Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027.